Human Genome Sciences Rejects GSK Offer

Apr 20, 2012, 00:10 AM by Michael Croft

Bloomberg BusinessWeek | In a second buyout rejection this week, Human Genome Sciences rejected a $2.59 billion acquisition bid from GlaxoSmithKline. The two companies currently partner on a lupus treatment.

April 20, 2012 | In a second buyout rejection this week, Human Genome Sciences rejected a $2.59 billion acquisition bid from GlaxoSmithKline. The two companies currently partner on a lupus treatment. Althought Human Genome refused the cash offer, the company is still for sale and may be hoping to stir up competiton and increase the offer. Bloomberg Businessweek